VIZAMYL

Drug GE HEALTHCARE
Total Payments
$417,407
Transactions
40
Doctors
16
Companies
2

Payment Trends by Year

Year Amount Transactions Doctors
2022 $363,040 8 0
2021 $36,805 19 10
2020 $15,162 12 6
2017 $2,400 1 1

Payments by Nature

Nature of Payment Amount Transactions Share
Unspecified $363,040 8 87.0%
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $36,805 19 8.8%
Consulting Fee $17,562 13 4.2%

Payments by Type

Research
$363,040
8 transactions
General
$54,367
32 transactions

Research Studies & Clinical Trials

Study Name Sponsor Amount Doctors
CT COLLABORATION ON AI TECHNIQUES GE HEALTHCARE $160,905 0
NEW IDEAS STUDY CLINICAL RESEARCH GE HEALTHCARE $133,826 0
A DESCRIPTIVE| COMPARATIVE| RANDOMIZED| CROSSOVER STUDY OF FLURPIRIDAZ (18F) INJECTION FOR POSITRON EMISSION TOMOGRAPHY (PET) IMAGING FOR ASSESSMENT OF MYOCARDIAL PERFUSION IMAGING QUALITY USING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC) AND SOLID PHASE EXREACTION (SPE) MANUFACTURING PROCESSES GE HEALTHCARE $68,309 0

Top Doctors Receiving Payments for VIZAMYL

Doctor Specialty Location Total Records
Unknown Phoenix, AZ $363,840 9
, MD,PHD Specialist Pittsburgh, PA $8,855 2
, MD Neurology Philadelphia, PA $7,200 2
, MD Neurology Hattiesburg, MS $6,800 4
, MD Neurology West Palm Beach, FL $4,800 3
, M.D. PH.D Nuclear Radiology Hamden, CT $3,200 2
, MD Advanced Heart Failure and Transplant Cardiology Chattanooga, TN $2,527 2
, MD Interventional Cardiology Atlanta, GA $2,527 2
, M.D Nuclear Cardiology Chattanooga, TN $2,527 2
, MD Cardiovascular Disease Salt Lake City, UT $2,527 2
, M.D Internal Medicine Tallahassee, FL $2,527 2
, MD Interventional Cardiology Kingsport, TN $2,527 2
, M.D Neurology Rochester, MN $2,400 2
, MD Neurology San Diego, CA $1,800 1
, MD Neurology Providence, RI $1,250 1
, M.D Nephrology Mill Valley, CA $1,200 1
, MD Behavioral Neurology & Neuropsychiatry Silver Spring, MD $900.00 1

About VIZAMYL

VIZAMYL is a drug associated with $417,407 in payments to 16 healthcare providers, recorded across 40 transactions in the CMS Open Payments database. The primary manufacturer is GE HEALTHCARE.

Payment data is available from 2017 to 2022. In 2022, $363,040 was paid across 8 transactions to 0 doctors.

The most common payment nature for VIZAMYL is "Unspecified" ($363,040, 87.0% of total).

VIZAMYL is associated with 3 research studies, including "CT COLLABORATION ON AI TECHNIQUES" ($160,905).